Detailansicht

Wissensnetz

Person

Kaj Blennow

Hochschullehrer

Name	Kaj Blennow
Zeit	1999- (Wirkungsdaten)
Ort	Schweden
Geschlecht	männlich
Akademischer Grad bzw. Titel	Prof. Dr.
Beruf	Hochschullehrer (charakteristischer Beruf)
Beziehung	Göteborgs universitet Neurochemie (Thema) Alzheimerkrankheit (Thema)
Quelle	https://www.gu.se/en/about/find-staff/kajblennow (Stand: 07.01.2025)
Datensatztyp	Person
GND-Nummer	1261078578
Datensatz-ID	1261078578
Beteiligt an alle anzeigen Diagnosis of Alzheimer’s disease using plasma biomarkers adjusted to clinical probability Peripheral innate immunophenotype in neurodegenerative disease: blood-based profiles and links to survival Sex/gender effects of glial reactivity on preclinical Alzheimer’s disease pathology Blood biomarkers of neuronal injury and astrocytic reactivity in electroconvulsive therapy Gene-variant specific effects of plasma amyloid-β levels in Swedish autosomal dominant Alzheimer disease Neurofilament light chain associates with IVH and ROP in extremely preterm infants Neuroinflammation, cerebrovascular dysfunction and diurnal cortisol biomarkers in a memory clinic cohort: Findings from the Co-STAR study Plasma NfL, GFAP, amyloid, and p-tau species as Prognostic biomarkers in Parkinson’s disease CSF neurogranin levels as a biomarker in Alzheimer’s disease and frontotemporal lobar degeneration: a cross-sectional analysis Serum neurofilament light at diagnosis: a prognostic indicator for accelerated disease progression in Parkinson’s Disease Plasma neurofilament light, glial fibrillary acid protein, and phosphorylated tau 181 as biomarkers for neuropsychiatric symptoms and related clinical disease progression 18F-Flortaucipir (AV1451) imaging identifies grey matter atrophy in retired athletes Hormone therapy is associated with lower Alzheimer’s disease tau biomarkers in post-menopausal females -evidence from two independent cohorts Tau protein profiling in tauopathies: a human brain study Involvement of the choroid plexus in Alzheimer’s disease pathophysiology: findings from mouse and human proteomic studies Amyloid-β peptide signature associated with cerebral amyloid angiopathy in familial Alzheimer’s disease with APPdup and Down syndrome Circulating levels of neurofilament light chain as a biomarker of infarct and white matter hyperintensity volumes after ischemic stroke PTPRS is a novel marker for early Tau pathology and synaptic integrity in Alzheimer’s disease Effects of time of the day at sampling on CSF and plasma levels of Alzheimer’ disease biomarkers Effects of Oral ALZ-801/Valiltramiprosate on Plasma Biomarkers, Brain Hippocampal Volume, and Cognition: Results of 2-Year Single-Arm, Open-Label, Phase 2 Trial in APOE4 Carriers with Early Alzheimer’s Disease The relation of synaptic biomarkers with Aβ, tau, glial activation, and neurodegeneration in Alzheimer’s disease Acute-Phase Neurofilament Light and Glial Fibrillary Acidic Proteins in Cerebrospinal Fluid Predict Long-Term Outcome After Severe Traumatic Brain Injury Variants in the MS4A cluster interact with soluble TREM2 expression on biomarkers of neuropathology Blood biomarkers of neurodegeneration associate differently with amyloid deposition, medial temporal atrophy, and cerebrovascular changes in APOE ε4-enriched cognitively unimpaired elderly p75 neurotrophin receptor modulation in mild to moderate Alzheimer disease: a randomized, placebo-controlled phase 2a trial The neutrophil to lymphocyte ratio associates with markers of Alzheimer’s disease pathology in cognitively unimpaired elderly people Comparison of plasma and neuroimaging biomarkers to predict cognitive decline in non-demented memory clinic patients Alzheimer blood biomarkers: practical guidelines for study design, sample collection, processing, biobanking, measurement and result reporting Plasma biomarkers increase diagnostic confidence in patients with Alzheimer’s disease or frontotemporal lobar degeneration Personalized whole-brain neural mass models reveal combined Aβ and tau hyperexcitable influences in Alzheimer’s disease Cerebrospinal fluid reference proteins increase accuracy and interpretability of biomarkers for brain diseases Chronic immunosuppression across 12 months and high ability of acute and subacute CNS-injury biomarker concentrations to identify individuals with complicated mTBI on acute CT and MRI Association of serum glial fibrillary acidic protein with progression independent of relapse activity in multiple sclerosis Plasma glial fibrillary acidic protein and tau: predictors of neurological outcome after cardiac arrest Functional connectivity changes in neurodegenerative biomarker-positive athletes with repeated concussions Plasma brain-derived tau is an amyloid-associated neurodegeneration biomarker in Alzheimer’s disease Plasma concentrations of glial fibrillary acidic protein, neurofilament light, and tau in Alexander disease Plasma p-tau212 antemortem diagnostic performance and prediction of autopsy verification of Alzheimer’s disease neuropathology Correction to: Neurofilament light in plasma is a potential biomarker of central nervous system involvement in systemic lupus erythematosus A blood-based biomarker workflow for optimal tau-PET referral in memory clinic settings Low CD4 + T cell count is related to specific anti-nuclear antibodies, IFNα protein positivity and disease activity in systemic lupus erythematosus pregnancy Repetitive head injuries in German American football players do not change blood-based biomarker candidates for CTE during a single season Plasma N-terminal containing tau fragments (NTA-tau): a biomarker of tau deposition in Alzheimer’s Disease Inflammatory biomarkers for neurobehavioral dysregulation in former American football players: findings from the DIAGNOSE CTE Research Project Biomarkers for neurodegeneration impact cognitive function: a longitudinal 1-year case–control study of patients with bipolar disorder and healthy control individuals Head-to-head study of diagnostic accuracy of plasma and cerebrospinal fluid p-tau217 versus p-tau181 and p-tau231 in a memory clinic cohort Comparison of immunoassay- with mass spectrometry-derived p-tau quantification for the detection of Alzheimer’s disease pathology CSF p-tau205: a biomarker of tau pathology in Alzheimer’s disease Elevated CSF angiopoietin-2 correlates with blood-brain barrier leakiness and markers of neuronal injury in early Alzheimer’s disease Elevated CSF GAP-43 is associated with accelerated tau accumulation and spread in Alzheimer’s disease The Taxonomy of Subjective Cognitive Decline: Proposal and First Clinical Evidence from the Geneva Memory Clinic Cohort Neuro-Specific and Immuno-Inflammatory Biomarkers in Umbilical Cord Blood in Neonatal Hypoxic-Ischemic Encephalopathy Development and multi-center validation of a fully automated digital immunoassay for neurofilament light chain: toward a clinical blood test for neuronal injury Optimal blood tau species for the detection of Alzheimer’s disease neuropathology: an immunoprecipitation mass spectrometry and autopsy study Longitudinal cerebrospinal fluid measurements show glial hypo- and hyperactivation in predementia Alzheimer’s disease 14-3-3 $$\upzeta /\updelta$$ ζ Plasma GFAP and its association with disease severity in Huntington’s disease Gut inflammation associated with age and Alzheimer’s disease pathology: a human cohort study Comparison of CSF and plasma NfL and pNfH for Alzheimer’s disease diagnosis: a memory clinic study Differential patterns of lysosomal dysfunction are seen in the clinicopathological forms of primary progressive aphasia

Hinweis

Die Betaversion beinhaltet noch nicht alle Funktionen und Informationen des Katalogs des DNB-Portals. Falls Sie Informationen vermissen oder ein Medium bestellen wollen, besuchen Sie bitte die entsprechende Seite im Katalog des DNB-Portals über folgenden Link:

Katalog der Deutschen Nationalbibliothek

Kaj Blennow

Diagnosis of Alzheimer’s disease using plasma biomarkers adjusted to clinical probability

Peripheral innate immunophenotype in neurodegenerative disease: blood-based profiles and links to survival

Sex/gender effects of glial reactivity on preclinical Alzheimer’s disease pathology

Blood biomarkers of neuronal injury and astrocytic reactivity in electroconvulsive therapy

Gene-variant specific effects of plasma amyloid-β levels in Swedish autosomal dominant Alzheimer disease

Neurofilament light chain associates with IVH and ROP in extremely preterm infants

Neuroinflammation, cerebrovascular dysfunction and diurnal cortisol biomarkers in a memory clinic cohort: Findings from the Co-STAR study

Plasma NfL, GFAP, amyloid, and p-tau species as Prognostic biomarkers in Parkinson’s disease

CSF neurogranin levels as a biomarker in Alzheimer’s disease and frontotemporal lobar degeneration: a cross-sectional analysis

Serum neurofilament light at diagnosis: a prognostic indicator for accelerated disease progression in Parkinson’s Disease

Plasma neurofilament light, glial fibrillary acid protein, and phosphorylated tau 181 as biomarkers for neuropsychiatric symptoms and related clinical disease progression

18F-Flortaucipir (AV1451) imaging identifies grey matter atrophy in retired athletes

Hormone therapy is associated with lower Alzheimer’s disease tau biomarkers in post-menopausal females -evidence from two independent cohorts

Tau protein profiling in tauopathies: a human brain study

Involvement of the choroid plexus in Alzheimer’s disease pathophysiology: findings from mouse and human proteomic studies

Amyloid-β peptide signature associated with cerebral amyloid angiopathy in familial Alzheimer’s disease with APPdup and Down syndrome

Circulating levels of neurofilament light chain as a biomarker of infarct and white matter hyperintensity volumes after ischemic stroke

PTPRS is a novel marker for early Tau pathology and synaptic integrity in Alzheimer’s disease

Effects of time of the day at sampling on CSF and plasma levels of Alzheimer’ disease biomarkers

Effects of Oral ALZ-801/Valiltramiprosate on Plasma Biomarkers, Brain Hippocampal Volume, and Cognition: Results of 2-Year Single-Arm, Open-Label, Phase 2 Trial in APOE4 Carriers with Early Alzheimer’s Disease

The relation of synaptic biomarkers with Aβ, tau, glial activation, and neurodegeneration in Alzheimer’s disease

Acute-Phase Neurofilament Light and Glial Fibrillary Acidic Proteins in Cerebrospinal Fluid Predict Long-Term Outcome After Severe Traumatic Brain Injury

Variants in the MS4A cluster interact with soluble TREM2 expression on biomarkers of neuropathology

Blood biomarkers of neurodegeneration associate differently with amyloid deposition, medial temporal atrophy, and cerebrovascular changes in APOE ε4-enriched cognitively unimpaired elderly

p75 neurotrophin receptor modulation in mild to moderate Alzheimer disease: a randomized, placebo-controlled phase 2a trial

The neutrophil to lymphocyte ratio associates with markers of Alzheimer’s disease pathology in cognitively unimpaired elderly people

Comparison of plasma and neuroimaging biomarkers to predict cognitive decline in non-demented memory clinic patients

Alzheimer blood biomarkers: practical guidelines for study design, sample collection, processing, biobanking, measurement and result reporting

Plasma biomarkers increase diagnostic confidence in patients with Alzheimer’s disease or frontotemporal lobar degeneration

Personalized whole-brain neural mass models reveal combined Aβ and tau hyperexcitable influences in Alzheimer’s disease

Cerebrospinal fluid reference proteins increase accuracy and interpretability of biomarkers for brain diseases

Chronic immunosuppression across 12 months and high ability of acute and subacute CNS-injury biomarker concentrations to identify individuals with complicated mTBI on acute CT and MRI

Association of serum glial fibrillary acidic protein with progression independent of relapse activity in multiple sclerosis

Plasma glial fibrillary acidic protein and tau: predictors of neurological outcome after cardiac arrest

Functional connectivity changes in neurodegenerative biomarker-positive athletes with repeated concussions

Plasma brain-derived tau is an amyloid-associated neurodegeneration biomarker in Alzheimer’s disease

Plasma concentrations of glial fibrillary acidic protein, neurofilament light, and tau in Alexander disease

Plasma p-tau212 antemortem diagnostic performance and prediction of autopsy verification of Alzheimer’s disease neuropathology

Correction to: Neurofilament light in plasma is a potential biomarker of central nervous system involvement in systemic lupus erythematosus

A blood-based biomarker workflow for optimal tau-PET referral in memory clinic settings

Low CD4 + T cell count is related to specific anti-nuclear antibodies, IFNα protein positivity and disease activity in systemic lupus erythematosus pregnancy

Repetitive head injuries in German American football players do not change blood-based biomarker candidates for CTE during a single season

Plasma N-terminal containing tau fragments (NTA-tau): a biomarker of tau deposition in Alzheimer’s Disease

Inflammatory biomarkers for neurobehavioral dysregulation in former American football players: findings from the DIAGNOSE CTE Research Project

Biomarkers for neurodegeneration impact cognitive function: a longitudinal 1-year case–control study of patients with bipolar disorder and healthy control individuals

Head-to-head study of diagnostic accuracy of plasma and cerebrospinal fluid p-tau217 versus p-tau181 and p-tau231 in a memory clinic cohort

Comparison of immunoassay- with mass spectrometry-derived p-tau quantification for the detection of Alzheimer’s disease pathology

CSF p-tau205: a biomarker of tau pathology in Alzheimer’s disease

Elevated CSF angiopoietin-2 correlates with blood-brain barrier leakiness and markers of neuronal injury in early Alzheimer’s disease

Elevated CSF GAP-43 is associated with accelerated tau accumulation and spread in Alzheimer’s disease

The Taxonomy of Subjective Cognitive Decline: Proposal and First Clinical Evidence from the Geneva Memory Clinic Cohort

Neuro-Specific and Immuno-Inflammatory Biomarkers in Umbilical Cord Blood in Neonatal Hypoxic-Ischemic Encephalopathy

Development and multi-center validation of a fully automated digital immunoassay for neurofilament light chain: toward a clinical blood test for neuronal injury

Optimal blood tau species for the detection of Alzheimer’s disease neuropathology: an immunoprecipitation mass spectrometry and autopsy study

Longitudinal cerebrospinal fluid measurements show glial hypo- and hyperactivation in predementia Alzheimer’s disease

14-3-3 $$\upzeta /\updelta$$ ζ

Plasma GFAP and its association with disease severity in Huntington’s disease

Gut inflammation associated with age and Alzheimer’s disease pathology: a human cohort study

Comparison of CSF and plasma NfL and pNfH for Alzheimer’s disease diagnosis: a memory clinic study

Differential patterns of lysosomal dysfunction are seen in the clinicopathological forms of primary progressive aphasia